May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Incidence of Punctate Epithelial Erosions (PEE) in Double-Masked, Prospective, Controlled Trials of Latanoprost versus Timolol
Author Affiliations & Notes
  • L.-J. Hwang
    Pfizer Inc, New York, New York
  • G. W. Bean
    TMA Associates, Burkett, Texas
  • J. M. Fain
    Pfizer Inc, New York, New York
  • M. B. Sultan
    Pfizer Inc, New York, New York
  • E. Kim
    Pfizer Inc, New York, New York
  • J. Grunden
    Pfizer Inc, New York, New York
  • C. S. Tressler
    Pfizer Inc, New York, New York
  • Footnotes
    Commercial Relationships  L. Hwang, Pfizer, E; G.W. Bean, Pfizer, C; J.M. Fain, Pfizer, E; M.B. Sultan, Pfizer, E; E. Kim, Pfizer, E; J. Grunden, Pfizer, E; C.S. Tressler, Pfizer, E.
  • Footnotes
    Support  Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1218. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.-J. Hwang, G. W. Bean, J. M. Fain, M. B. Sultan, E. Kim, J. Grunden, C. S. Tressler; The Incidence of Punctate Epithelial Erosions (PEE) in Double-Masked, Prospective, Controlled Trials of Latanoprost versus Timolol. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1218. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine whether doubling the amount of benzalkonium chloride (BAK) in latanoprost-treated patients was associated with an increased incidence of PEE in trials comparing latanoprost and timolol in patients with glaucoma or ocular hypertension.

Methods: : A meta-analysis of the double-masked phases of 6 prospective, controlled clinical trials compared the incidence of PEE among glaucoma or ocular hypertension patients assigned to treatment with latanoprost or timolol. Timolol maleate (0.01% BAK) was given twice daily and latanoprost (0.02% BAK) was given once daily with vehicle (0.01% or 0.02% BAK) given once daily in 5 of the 6 trials; 1 study dosed both drugs once daily. All patients reporting PEE either as a finding or an adverse event were included in the analysis.

Results: : Of the 1658 patients enrolled in the double-masked portion of the trials (latanoprost, n=874; timolol, n=784), the overall incidence of PEE was 6.4%. The incidence in latanoprost-treated patients was 6.6% and was 6.1% in those treated with timolol. The combined risk difference of latanoprost - timolol was 0.008 (95% CI: -0.015, 0.031; P=0.495), and the combined odds ratio of latanoprost versus timolol for PEE was 1.114 (95% CI: 0.726, 1.710; P=0.620). The amount of the preservative BAK was approximately twice as great in the latanoprost arm compared to the timolol arm.

Conclusions: : The incidence of PEE was similar and not statistically significantly different between latanoprost- and timolol-treated patients. Doubling the amount of BAK in the latanoprost arm was not associated with an increased incidence of PEE.

Keywords: cornea: epithelium • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×